CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 35 enrolled
Drug / intervention
Memantine +1 moredrug
Likely dose
Memantine 10 mg daily, increased to 10 mg twice dailyAI-extracted
Key inclusion· 2
  • ✓Admission to a skilled nursing facility for rehabilitation within 3 months of a recent disabling medical event (e.g., hip fracture)
  • ✓Medically stable, with no active seizures, delirium, or unstable vital signs
Key exclusion· 8
  • ✕Aphasia or cognitive impairment severe enough to prevent valid assessment (e.g., MMSE score <22)
  • ✕Current major depressive episode
  • ✕History of or current psychosis or mania
  • ✕Current substance or alcohol abuse or dependence within 3 months of study entry

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00183729
NCT00183729Phase 4Completed
CompareCT.gov

Memantine for Enhancement of Rehabilitation Efficacy and Prevention of Major Depressive Disorder in Older Adults

Eric Lenze·interventional·Posted Sep 16, 2005·Updated Jan 17, 2018

In Brief

A Phase 4 clinical trial evaluating Memantine and Placebo for Depression. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or cardiopulmonary condition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartAug 1, 2005
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 20.8 years ago

Interventions

Memantinedrug

Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.

Placeboother

Placebo distribution is planned to mimic the active drug.